Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Effect of Forex Changes

Change in reported cash caused by exchange-rate movements on foreign-currency balances.

Emergent BioSolutions Inc.NYSE: EBS

Effect of Forex Changes · Q1 FY2026 · quarter ended Mar 2026

Effect of forex changes turns positive

Q1 FY2026 effect of forex changes was $0, compared with -$700K a year earlier. Trailing-twelve-month effect of forex changes was $800K. Over 3 fiscal years it compounded at -41.5% a year.

Context

  • Effect of forex changes amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Effect of forex changes increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly effect of forex changes holds near $0 or moves back toward the trailing-twelve-month quarterly average of $200K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$100K— YoY
LTMMar 2026
$800K+214.3% YoY
Effect of Forex Changes past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year———
3-year CAGR-41.5%——
5-year CAGR——
10-year CAGR——

Effect of Forex Changes history

USD · from the cash flow

Latest · FY2025
100K USD
Year-over-year change
—

Effect of Forex Changes vs competitors

How EBS compares with its peers on the latest reported figures

  • Peers report in different currencies, so effect of forex changes is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +214.3% is the lowest of 2, against a peer median of +369.8%.
  • Effect of forex changes amounts to 0.1% of revenue for EBS, versus a peer median of 0.0%.
EBS Competitors
Effect of Forex Changes for EBS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNDLSNDL Inc.LTM Mar 2026CA$12.14M CAD——1.3%
CMPSCOMPASS Pathways plcLTM Mar 2026$2.61M USD+369.8%——
EBSEmergent BioSolutions Inc.LTM Mar 2026$800K USD+214.3%-41.5%0.1%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$0 USD——0.0%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
ESPREsperion Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
PRTAProthena Corporation plcLTM Mar 2026$0 USD——0.0%
SIGASIGA Technologies, Inc.LTM Mar 2026$0 USD——0.0%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding EBS) —+369.8%—0.0%

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income230.9M(211.6M)(760.5M)(190.6M)52.6M
Depreciation & Amortization123.8M143.3M125.1M108.8M95.8M
Deferred Income Tax46.9M(28.6M)(8.9M)(5.5M)(4M)
Stock-Based Compensation42.4M45.1M23.1M18M16.2M
Change in Working Capital(156.4M)(2.1M)(70.3M)88.7M(22.4M)
Accounts Receivables(48.2M)118.1M(21.6M)(24.4M)25.5M
Inventory(44M)(57.1M)600K(24.5M)(30.3M)
Accounts Payables(2.5M)(14M)10.6M(33M)(8.4M)
Other Working Capital(61.7M)(49.1M)(59.9M)170.6M(9.2M)
Other Non-Cash Items33.5M19.8M485.2M39.3M32.4M
Operating Cash Flow321.1M(34.1M)(206.3M)58.7M170.6M
Capital Expenditures(225M)(115.8M)(51.6M)(22.9M)(13.8M)
Acquisitions (Net)00270.2M00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(265.5M)(6.3M)148.1M83.2M
Investing Cash Flow(225M)(381.3M)212.3M125.2M69.4M
Debt Repayment(35.9M)564.2M(543.4M)(198.4M)(112.5M)
Common Stock Issued008.4M9.3M2.2M
Common Stock Repurchased(106M)(82.1M)00(24.9M)
Dividends Paid00000
Other Financing Activities900K(900K)(700K)(900K)(1.4M)
Financing Cash Flow(141M)481.2M(535.7M)(190M)(136.6M)
Effect of Forex Changes(300K)500K(1.2M)0100K
Net Change in Cash(45.2M)66.3M(530.9M)(6.1M)103.5M
Free Cash Flow96.1M(149.9M)(257.9M)35.8M156.8M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.